CNQX-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•Agonists•ScreeningLibrarieswww.MedChemECNQXCat.No.:HY-15066CASNo.:115066-14-3分⼦式:C₉H₄N₄O₄分⼦量:232.15作⽤靶点:iGluR作⽤通路:MembraneTransporter/IonChannel;NeuronalSignaling储存⽅式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验DMSO:25mg/mL(107.69mM;Needultrasonic)扫描⼆维码，H2O:<0.1mg/mL(insoluble)运⽤溶解⽅案计算器获得适合您实验体系的溶解⽅案MassSolvent1mg5mg10mgConcentration制备储备液1mM4.3076mL21.5378mL43.0756mL5mM0.8615mL4.3076mL8.6151mL10mM0.4308mL2.1538mL4.3076mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存⽅式和期限。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶1.请依序添加每种溶剂：10%DMSO40%PEG3005%Tween-8045%salineSolubility:≥2.08mg/mL(8.96mM);Clearsolution此⽅案可获得≥2.08mg/mL(8.96mM，饱和度未知)的澄溶液。以1mL⼯作液为例，取100μL20.8mg/mL的澄DMSO储备液加到400μLPEG300中，混合均匀；向上述体系中加⼊50μLTween-80，混合均匀；然后继续加⼊450μL⽣理盐⽔定容⾄1mL。1/3www.MedChemEwww.MedChemE2.请依序添加每种溶剂：10%DMSO90%(20%SBE-β-CDinsaline)Solubility:2.08mg/mL(8.96mM);Suspendedsolution;Needultrasonic此⽅案可获得2.08mg/mL(8.96mM)的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。以1mL⼯作液为例，取100μL20.8mg/mL的澄DMSO储备液加到900μL20%的SBE-β-CD⽣理盐⽔⽔溶液中，混合均匀。BIOLOGICALACTIVITY⽣物活性CNQX(FG9065)⼀种有效的竞争性AMPA/海藻酸酯受体(AMPA/kainatereceptor)拮抗剂，IC50分别为0.3μM和1.5μM。CNQX⼀种竞争性的⾮NMDA受体拮抗剂。CNQX会阻⽌⼤⿏恐增强的表达。IC50&TargetIC50:0.3μM(AMPA)and1.5μM(kainatereceptor)[1]体外研究CNQX(FG9065;2-5μM)reversiblyblockstheSchaffercollateralandmossyfibreexcitatorypostsynapticpotential(EPSP),whilesparingthefastandslowGABA-mediatedinhibitioninsuperfusionofhippocampalslices[2].CNQX(1-5μM)producesaselectiveanddose-dependentreductionintheamplitudeofthemonosynapticcomponentoftheDR-VRRrecordedfromlumbarspinalsegments[3].体内研究CNQX(FG9065;2-5μM)reversiblyblockstheSchaffercollateralandmossyfibreexcitatorypostsynapticpotential(EPSP),whilesparingthefastandslowGABA-mediatedinhibitioninsuperfusionofhippocampalslices[2].CNQX(1-5μM)producesaselectiveanddose-dependentreductionintheamplitudeofthemonosynapticcomponentoftheDR-VRRrecordedfromlumbarspinalsegments[3].AnimalModel:MaleWistarratsweighing180-200g[4]Dosage:0.75,1.5,and3mg/kgAdministration:IP;20minbeforetestingResult:Decreasedthenumberofcocaine(IV;0.25mg/infusion)responsesinadose-dependentmannerduringthefirst15-mincocaine-freeinterval户使⽤本产品发表的科研⽂献•FrontCellNeurosci.2019Jun25;13:276.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].THonoré,etal.Quinoxalinediones:PotentCompetitivenon-NMDAGlutamateReceptorAntagonists.Science.1988Aug2/3www.MedChemEwww.MedChemE5;241(4866):701-3.[2].NeumanRS,etal.Blockadeofexcitatorysynaptictransmissionby6-cyano-7-nitroquinoxaline-2,3-dione(CNQX)inthehippocampusinvitro.NeurosciLett.1988Sep23;92(1):64-8.[3].AlfordS,etal.CNQXandDNQXblocknon-NMDAsynaptictransmissionbutnotNMDA-evokedlocomotioninlampreyspinalcord.BrainRes.1990Jan8;506(2):297-302.[4].PiaBäckström,etal.AttenuationofCocaine-SeekingBehaviourbytheAMPA/kainateReceptorAntagonistCNQXinRats.Psychopharmacology(Berl).2003Feb;166(1):69-76.[5].KimM,etal.Infusionofthenon-NMDAreceptorantagonistCNQXintotheamygdalablockstheexpressionoffear-potentiatedstartle.BehavNeuralBiol.1993Jan;59(1):5-8.McePdfHeight关注MCE中国公众号，

获取前沿资讯、最新活动和

实⽤科研⼯具MedChemExpress(MCE)只为有资质的科研机构、医药企业基于科学研究或药证申报的